Development of Novel Gastrointestinal Biomarkers for Use in HIV Incidence Determination in a Sub-Saharan African Setting

Foto: Photo: César Velasco

The earliest phase of HIV infection is clinically important in determining the natural history of disease. It is also the moment in which much of the immune damage occurs and constitutes the most infectious stage of the infection. Development of a test which could distinguish between individuals with early or longstanding HIV infection could potentially be used for clinical management, but would also allow the estimation of an HIV incidence rate.

The primary aim of GAMA is to gain a better understanding of dynamics of biomarkers of gastrointestinal inflammation during the first year of HIV infection as compared to chronic infection. The tremendous damage inflicted on the gut-associated lymphoid tissue during early HIV infection may provide the opportunity to identify biomarkers which present altered expression during the early phases of HIV infection. GAMA will assess the utility of these markers for identifying recent HIV infection as well as for potential associations with progression to AIDS. Understanding the dynamics of these biomarkers and associating them with standard serological responses during early HIV infection may reveal specific changes in expression patterns of biomarkers which are able to distinguish early from longstanding HIV infection.

Development of an assay for measuring HIV incidence would facilitate the evaluation of ongoing prevention programs as well as the design and implementation of trials to evaluate new prevention interventions.

Project Funders

Main Funders: Bill & Mellinda Gates Foundation

Co-funding: Ministry of Economy and Competitiveness. Government of Spain

Nuestro equipo

Principal Investigator (PI)

  • Denise Suzanne Naniche
    Denise Suzanne Naniche

Otros proyectos

Ver proyectos pasados


Linkage and retention in care following home-based HIV testing serosurveys in Manhiça District, Southern Mozambique


Improved case detection through TB contact risk stratification by Xpert results and spatial parameters in Mozambique


Evaluation of the effect of weekly high dose rifapentine and isoniazid (3HP) vs periodic 3HP vs 6H for preventing TB among HIV-positive individuals


Measuring community prevalence among HIV exposed children in rural Southern Mozambique


Improving Maternal and Infant Health by reducing malaria risks in African women: evaluation of the safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in HIV-infected pregnant women


Optimizing provider-initiated HIV testing, linkage, and retention in care in the district of Manhiça, Mozambique


Integrating and decentralizing diabetes and hypertension services in Africa


Predicting the Future: Incipient Tuberculosis

2G Color Plates

2nd Generation Color Agar Plates to Diagnose MDR-Tuberculosis: a Prospective Pilot Study